Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6 Mln
P/E Ratio
--
P/B Ratio
65.82
Industry P/E
--
Debt to Equity
-0.09
ROE
-11.22 %
ROCE
-207 %
Div. Yield
0 %
Book Value
--
EPS
2.19
CFO
$-144.99 Mln
EBITDA
$-162.30 Mln
Net Profit
$-162.24 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Brainstorm Cell Therapeutics (BCLI)
| -57.05 | -28.83 | -55.48 | -88.07 | -72.40 | -59.64 | -33.99 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Brainstorm Cell Therapeutics (BCLI)
| -44.30 | -83.35 | -59.00 | -11.60 | 5.72 | 20.56 | -9.39 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy... platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Read more
President & Co-CEO
Mr. Chaim Lebovits
President & Co-CEO
Mr. Chaim Lebovits
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Brainstorm Cell Therapeutics Inc (BCLI) stood at $ 2 Mln as on 31-Dec-24
The share price of Brainstorm Cell Therapeutics Inc (BCLI) is $0.98 (NASDAQ) as of 25-Apr-2025 16:23 EDT. Brainstorm Cell Therapeutics Inc (BCLI) has given a return of -72.4% in the last 3 years.
Brainstorm Cell Therapeutics Inc (BCLI) has a market capitalisation of $ 6 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Brainstorm Cell Therapeutics Inc (BCLI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Brainstorm Cell Therapeutics Inc (BCLI) and enter the required number of quantities and click on buy to purchase the shares of Brainstorm Cell Therapeutics Inc (BCLI).
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
The CEO & director of Mr. Chaim Lebovits. is Brainstorm Cell Therapeutics Inc (BCLI), and CFO & Sr. VP is Mr. Chaim Lebovits.
There is no promoter pledging in Brainstorm Cell Therapeutics Inc (BCLI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Brainstorm Cell Therapeutics Inc. (BCLI) | Ratios |
|---|---|
|
Return on equity(%)
|
-184.17
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
1369.02
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Brainstorm Cell Therapeutics Inc (BCLI) was $0 Mln.
$0.06
(
